Clinical trials: JIA
Juvenile Idiopathic Arthritis
Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis
A randomized double blind clinical trial to assess efficacy of leflunomide in treatment of refractory juvenile idiopathic arthritis. Patients are randomly divided into two groups.
- Trial name
- JIA (NCT02024334)
- Testing
- Leflunomide
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Mashhad University of Medical Sciences
Juvenile Idiopathic Arthritis (JIA)
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
Biologic therapies made clinical remission an achievable goal for most juvenile idiopathic arthritis (JIA) patients. Nevertheless, antirheumatic drugs have side effects and are costly.
- Trial name
- Re-JIA (NCT06618937)
- Testing
- Treatment medication withdrawal strategy
- Where
- Italy
- Volunteers
- 166 people
- Sponsor
- Istituto Giannina Gaslini
Scoliosis, Juvenile Idiopathic Arthritis
Spine Deformities in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA)is the most common chronic rheumatic disease in childhood. While JIA usually affects the ankle and knee joints, it can also affect hip, cervical spine and shoulder involvement.
- Conditions
- Scoliosis, Juvenile Idiopathic Arthritis, Awareness
- Trial name
- Scoliosis (NCT04664231)
- Where
- Turkey (Türkiye)
- Volunteers
- 257 people
- Sponsor
- Biruni University
JIA, Self-Evaluation
Using Self-evaluation to Increase Visit Intervals in Juvenile Idiopathic Arthritis
In the THUIS study, JIA patients in clinical remission will skip one 3-monthly hospital control visit and instead monitor their disease activity at home. Outcomes at 6 months will be compared to those from a historical cohort.
- Trial name
- THUIS (NCT05603286)
- Testing
- Home-monitoring
- Where
- Netherlands
- Volunteers
- 85 people
- Sponsor
- Joeri van Straalen
Rheumatic Diseases, Pediatric ALL
Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire
No tool has been found to evaluate behaviors that may hinder or facilitate physical activity in individuals with pediatric rheumatic diseases.
- Conditions
- Rheumatic Diseases, Pediatric ALL, Children, Only
- Trial name
- NCT06460766
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Istanbul University - Cerrahpasa
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Juvenile Idiopathic Arthritis (JIA), Familial Mediterranean Fever (FMF )
Gait Profile and Variables in Pediatric Rheumatic Disease Using a Smart Insole System
In pediatric rheumatic diseases, joint swelling, effusion, tenderness, and painful restriction of joint movement, particularly in weight-bearing joints, frequently alter walking function.
- Conditions
- Juvenile Idiopathic Arthritis (JIA), Familial Mediterranean Fever (FMF ), Healthy Controls
- Trial name
- NCT06705673
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Juvenile Idiopathic Arthritis
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)
This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.
- Trial name
- JIGSAW 117 (NCT01904279)
- Testing
- Tocilizumab
- Where
- 35 sites in United States, Argentina and 10 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Juvenile
Sleep & Pain in Juvenile Arthritis
Childhood arthritis is an important cause of pain for affected children and youth (adolescents). Many youth with arthritis also have trouble sleeping.
- Trial name
- NCT04133662
- Testing
- Sleep Manipulation Protocol
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- The Hospital for Sick Children
Juvenile Idiopathic Arthritis
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a multi-center, open-label single-arm study to investigate the pharmacokinetics and safety of tocilizumab (RoActemra/Actemra) in participants less than 2 years old with active sJIA.
- Trial name
- NCT01455701
- Testing
- Tocilizumab
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).
Inhibitors of tumour necrosis factor (TNFa) reduce inflammation in patients with juvenile idiopathic arthritis (JIA), but only 20-40 percent achieve a state of no or very little disease activity.
- Trial name
- MyJIA (NCT04614311)
- Testing
- Triamcinolone Hexacetonide 20 MG/ML
- Where
- 5 sites in Norway
- Volunteers
- 189 people
- Sponsor
- Oslo University Hospital
Juvenile Idiopathic Arthritis
Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis
Purpose and aims This as a pilot study that aims to investigate which inflammatory biomarkers can be found in saliva in children with Juvenile Idiopathic Arthritis (JIA).
- Trial name
- NCT02223195
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Folktandvården Stockholms län AB
Healthy Volunteers
A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants
The purpose of this study is to assess the PK comparability and compare safety and tolerability of DRL_AB administered via an auto injector (AI) or prefilled syringe (PFS) in healthy male participants.
- Trial name
- NCT07744828
- Testing
- DRL_AB
- Where
- 3 sites in New Zealand
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Still Disease, Juvenile Onset
Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
The purpose of the study is to evaluate and characterize long-term safety of Kineret when used in standard clinical practice to treat patients with systemic juvenile idiopathic arthritis (SJIA).
- Trial name
- NCT03932344
- Testing
- Anakinra
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Swedish Orphan Biovitrum
Juvenile Idiopathic Arthritis (JIA)
Reliability and Validity of the Glittre Activities of Daily Living Test in Children and Adolescents With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is children's most common inflammatory rheumatic disease. The International League of Associations for Rheumatology (ILAR) defines it as a chronic arthritis condition that begins before the age…
- Trial name
- NCT06806774
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Hacettepe University
Juvenile Idiopathic Arthritis, Arthritis, Septic
Rapid Diagnostic Test for Septic Arthritis
Diagnostic Validation Study of a Test Based on the Analysis of the Proteome by Mass Spectrometry for the Diagnosis of Septic Arthritis in Children Under 16 Years of Age
- Conditions
- Juvenile Idiopathic Arthritis, Arthritis, Septic, Arthritis, Unspecified
- Trial name
- TDR-Arthrite (NCT04460144)
- Testing
- Mass spectrometry
- Where
- France
- Volunteers
- 274 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks)…
- Trial name
- NCT07517575
- Testing
- OKZ q4w
- Where
- 14 sites in Russia
- Volunteers
- 71 people
- Sponsor
- R-Pharm International, LLC
Juvenile Rheumatoid Arthritis
Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis
OBJECTIVES: I. Determine the efficacy and safety of gammalinolenic acid in the treatment of childhood arthritis.
- Trial name
- NCT00004420
- Testing
- gamma-Linolenic acid
- Volunteers
- 50 people
- Sponsor
- FDA Office of Orphan Products Development
Juvenile Idiopathic Arthritis (JIA)
Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis
The goal of this clinical trial is to learn whether children and adolescents with juvenile idiopathic arthritis (JIA) who have had inactive disease for a long time can safely discontinue treatment with a tumour necrosis factor…
- Trial name
- The Treat-JIA (NCT07904780)
- Testing
- Adalimumab, Etanercept, Golimumab
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Oslo University Hospital
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche